Popular Posts

Tuesday 28 November 2017

Hikma invests in digital health firm Biolinq


Hikma Pharmaceuticals PLC (Hikma) said that its venture capital arm, Hikma Ventures Limited (Hikma Ventures) has invested in Biolinq, the next generation minimally-invasive biosensor technology company, in collaboration with M Ventures which led the $10 million series A round of financing.
Lana Ghanem, managing director of Hikma Ventures and Edward Kliphuis, investment director of the new businesses fund at M Ventures will be joining the Biolinq board of directors.
Biolinq is a digital health company with a unique, wirelessly-enabled biosensor patch that is capable of continuously monitoring multiple biomarkers. Biolinq’s first commercial product, a unique minimally-invasive technology will allow patients with diabetes to continuously monitor their blood glucose without the pain and hassle of traditional continuous glucose monitoring (CGM) systems.
“Diabetes is a chronic disease affecting millions of people worldwide with a high prevalence in the Middle East and North Africa. We enjoyed working alongside the M Ventures team on closing this investment and we look forward to working with the Biolinq team and our other co-investors to bring this technology to patients,” said Lana Ghanem.

No comments:

Post a Comment